Avadel pharmaceuticals to present at upcoming november 2020 investor conferences

Dublin, ireland, nov. 11, 2020 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the avadel management team will present at both the stifel virtual healthcare conference and the jefferies virtual london healthcare conference that are being held in november 2020.
AVDL Ratings Summary
AVDL Quant Ranking